Trials / Conditions / Raynaud's Phenomenon Secondary to Systemic Sclerosis
Raynaud's Phenomenon Secondary to Systemic Sclerosis
4 registered clinical trials studyying Raynaud's Phenomenon Secondary to Systemic Sclerosis.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Terminated | A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phe NCT04915950 | Pfizer | Phase 2 |
| Completed | Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase NCT04040322 | Civi Biopharma, Inc. | Phase 3 |
| Completed | Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Seco NCT02228850 | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | Phase 2 |
| Completed | Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis NCT02260557 | Actelion | Phase 2 |